Apalutamide and Overall Survival in Prostate Cancer.

MR, Smith; F, Saad; S, Chowdhury; S, Oudard; BA, Hadaschik; JN, Graff; D, Olmos; PN, Mainwaring; JY, Lee; H, Uemura; Porre P, De; AA, Smith; SD, Brookman-May; S, Li; K, Zhang; B, Rooney; A, Lopez-Gitlitz; EJ, Small

doi:10.1016/j.eururo.2020.08.011

Public

Apalutamide and Overall Survival in Prostate Cancer.

Shared by NobleBlocks on Sep 6, 2020 • 12:00 AM UTC

Authors:

Smith MR

Saad F

Chowdhury S

Abstract

<h4>Background</h4>The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate-specific antigen doubling time of ≤10 mo. At primary analysis, apalutamide improved median metastasis-free survival (MFS) by 2 y...

Subject

Overall Survival

Subsequent Therapy

Apalutamide

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!